“Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating cancer, announced their collaboration with the VA Greater Los Angeles Healthcare System (VAGLAHS) on Progenics’ AI research program. The collaborative AI research program aims to apply machine learning to medical imaging modalities, enabling standardized, information-driven healthcare practices in prostate cancer. The project is the nation’s first collaborative effort to validate cutting-edge machine learning tools for improving treatment management of Veterans with prostate cancer.” Read the full press release here.
Source: Progenics Pharmaceuticals Announces Collaboration With Veterans Affairs on the AI Research Program for Medical Image Analysis – July 25, 2019. Progenics.
